Literature DB >> 2523807

Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci.

E Mini1, A Novelli, T Mazzei, P Periti.   

Abstract

The in vitro activity of DuP 721 and DuP 105, two orally active members of the oxazolidinones, was compared with that of glycopeptides and ciprofloxacin against 185 gram-positive isolates. Ninety percent of Staphylococcus aureus isolates, including penicillin- and methicillin-resistant strains, were inhibited by DuP 721 at 1 micrograms/ml and by DuP 105 at 16 micrograms/ml; DuP 721 inhibited 90% of coagulase-negative staphylococci tested at 1 micrograms/ml. The MIC90 for Streptococcus faecalis was 4 micrograms/ml with DuP 721 and 16 micrograms/ml with DuP 105; DuP 721 inhibited 90% of beta-hemolytic streptococci of group A at 0.5 micrograms/ml. Similar results on selected strains were obtained by continuously recording the optical density of cultures.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523807     DOI: 10.1007/bf01965273

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis.

Authors:  D C Eustice; P A Feldman; A M Slee
Journal:  Biochem Biophys Res Commun       Date:  1988-02-15       Impact factor: 3.575

2.  In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones.

Authors:  W Brumfitt; J M Hamilton-Miller
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

3.  In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents.

Authors:  A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

4.  In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.

Authors:  H C Neu; A Novelli; G Saha; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

5.  Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.

Authors:  J S Daly; G M Eliopoulos; E Reiszner; R C Moellering
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

6.  Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.

Authors:  A M Slee; M A Wuonola; R J McRipley; I Zajac; M J Zawada; P T Bartholomew; W A Gregory; M Forbes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

  6 in total
  4 in total

1.  Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay.

Authors:  R W Murray; R D Schaadt; G E Zurenko; K R Marotti
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin.

Authors:  A H Lin; R W Murray; T J Vidmar; K R Marotti
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

3.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

4.  A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?

Authors:  G G Zhanel; C Shroeder; L Vercaigne; A S Gin; J Embil; D J Hoban
Journal:  Can J Infect Dis       Date:  2001-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.